Three conditions are central: the inherited variant must be strongly related to the exposure, independent of factors that could confound the exposure-outcome relationship, and connected to the health outcome only through that exposure. If any condition is doubtful, the genetic variant may not function as a valid instrumental variable, weakening the causal interpretation of the findings.
Alleles are randomly assigned during conception, so genetic differences can provide a natural source of exposure variation that is less shaped by later environmental or behavioral factors. This supports causal analysis when randomized trials are difficult, costly, or unethical. The approach does not remove the need to evaluate whether the selected variants satisfy the instrumental-variable assumptions.
Interpretation becomes problematic if a variant influences the outcome through a pathway other than the exposure being studied. That violates the requirement that the variant affect the outcome only through the exposure. Researchers therefore need to consider whether the observed genetic association reflects the proposed mechanism or an alternative biological route.
A typical analysis begins by identifying inherited variants associated with the exposure. Researchers then assess whether those variants are strongly related to the exposure, independent of confounding influences, and restricted to the proposed exposure pathway. Finally, they use the variants as instrumental variables to estimate whether differences in the exposure produce differences in the health outcome.
The method is valuable when a randomized trial would be difficult, expensive, or unethical to perform. It can examine whether biomarkers, lifestyle factors, diseases, or potential treatment targets have causal effects on health outcomes. Results may help distinguish causal relationships from associations and guide decisions about which questions deserve further clinical investigation.
By testing whether genetically influenced differences in an exposure correspond to differences in a health outcome, the method can provide evidence about the exposure's causal role in disease. This can help researchers move beyond observing that a biomarker or lifestyle factor is associated with illness, supporting more focused investigation of underlying disease mechanisms.
Evidence from the method can help prioritize potential drug targets by indicating whether influencing a biological exposure might affect a disease outcome. It may also highlight possible benefits or risks associated with that target before clinical research proceeds. In this way, genetic evidence can support decisions about which therapeutic hypotheses merit additional study.